Pipeline

We are driving forward a pipeline that leverages new targets and cutting-edge modalities to deliver transformative therapies to patients faster.

Filters

  • Diabetes
  • Immunology
  • Nephrology
  • Oncology
  • Ophthalmology
  • Other
  • Rare Diseases
  • Urology
  • Women's Health
  • Antibody
  • Antibody-drug conjugate (ADC)
  • Cell therapy
  • Gene therapy (AAV-based gene therapy)
  • Oncolytic virus
  • Pegylated RNA aptamer
  • Small molecule
  • Phase 1
  • Phase 2
  • Phase 3
  • Other
  • Filed

Legend: 

The compounds listed are investigational agents; there is no guarantee the agents will receive regulatory approval or become commercially available for the uses being investigated.

Therapeutic Area Name Target Disease Modality Classification

Licensor1

Phase2

No Results Found

Make sure all words are spelled correctly.


Try different keywords.


Try more general keywords.

This pipeline was last updated on October 30, 2025.

To access more detail about the current pipeline, please see the Supplemental Documents within the Financial Results library, available here.

1The Compounds with "In-house" in this column include those discovered by collaborative research.

2Compounds are developed globally unless noted. The most advanced development stage is shown for each indication. The right-facing arrow symbol means that the compound has been filed for regulatory approval.

3Approved as "VEOZA" in ex-US.

4Roxadustat ASP1517/FG-4592: Astellas has rights in Japan, Europe, the Commonwealth of Independent States, the Middle East, and South Africa.

5ASP546C/XNW27011: Astellas has worldwide rights excluding China's mainland, Hong Kong, Macau, and Taiwan.

6AT132 has been on FDA clinical hold since September 2021.